Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
Maze Therapeutics (NASDAQ: MAZE), a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for renal, metabolic and cardiovascular diseases, has announced its participation in the upcoming Jefferies 2025 Global Healthcare Conference. The company's CEO, Jason Coloma, Ph.D., will deliver a company overview presentation on Thursday, June 5, 2025 at 2 p.m. ET. Investors can access the live webcast through the Investors section of Maze's website at www.MazeTx.com, where it will remain archived for 60 days after the presentation.
Maze Therapeutics (NASDAQ: MAZE), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di farmaci di precisione a piccole molecole per malattie renali, metaboliche e cardiovascolari, ha annunciato la sua partecipazione alla prossima Jefferies 2025 Global Healthcare Conference. Il CEO dell'azienda, Jason Coloma, Ph.D., terrà una presentazione panoramica sull'azienda giovedì 5 giugno 2025 alle 14:00 ET. Gli investitori potranno seguire la diretta streaming nella sezione Investors del sito web di Maze all'indirizzo www.MazeTx.com, dove la registrazione resterà disponibile per 60 giorni dopo la presentazione.
Maze Therapeutics (NASDAQ: MAZE), una compañía biofarmacéutica en etapa clínica enfocada en desarrollar medicamentos de precisión de pequeñas moléculas para enfermedades renales, metabólicas y cardiovasculares, ha anunciado su participación en la próxima Jefferies 2025 Global Healthcare Conference. El CEO de la empresa, Jason Coloma, Ph.D., realizará una presentación general de la compañía el jueves 5 de junio de 2025 a las 2 p.m. ET. Los inversores podrán acceder a la transmisión en vivo a través de la sección de inversores del sitio web de Maze en www.MazeTx.com, donde estará archivada durante 60 días después de la presentación.
Maze Therapeutics (NASDAQ: MAZE)는 신장, 대사 및 심혈관 질환을 위한 소분자 정밀 의약품 개발에 주력하는 임상 단계의 바이오제약 회사로, 다가오는 Jefferies 2025 Global Healthcare Conference에 참여할 것임을 발표했습니다. 회사의 CEO인 Jason Coloma, Ph.D.가 2025년 6월 5일 목요일 오후 2시(동부시간)에 회사 개요 발표를 진행할 예정입니다. 투자자들은 Maze 웹사이트 www.MazeTx.com의 투자자 섹션을 통해 생중계 웹캐스트에 접속할 수 있으며, 발표 후 60일간 아카이브로 제공됩니다.
Maze Therapeutics (NASDAQ : MAZE), une société biopharmaceutique en phase clinique spécialisée dans le développement de médicaments de précision à petites molécules pour les maladies rénales, métaboliques et cardiovasculaires, a annoncé sa participation à la prochaine Jefferies 2025 Global Healthcare Conference. Le PDG de l'entreprise, Jason Coloma, Ph.D., présentera un aperçu de la société le jeudi 5 juin 2025 à 14h00 ET. Les investisseurs pourront accéder à la diffusion en direct via la section Investisseurs du site web de Maze à l'adresse www.MazeTx.com, où elle restera archivée pendant 60 jours après la présentation.
Maze Therapeutics (NASDAQ: MAZE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Präzisionsmedikamenten mit kleinen Molekülen für Nieren-, Stoffwechsel- und Herz-Kreislauf-Erkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies 2025 Global Healthcare Conference angekündigt. Der CEO des Unternehmens, Jason Coloma, Ph.D., wird am Donnerstag, den 5. Juni 2025 um 14 Uhr ET eine Unternehmenspräsentation halten. Investoren können den Live-Webcast über den Investor-Bereich der Maze-Website unter www.MazeTx.com verfolgen, wo er nach der Präsentation 60 Tage lang archiviert bleibt.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present a company overview at the Jefferies 2025 Global Healthcare Conference on Thursday, June 5, 2025 at 2 p.m. ET.
A live webcast will be available in the Investors section of the company's website at www.MazeTx.com and archived for 60 days following the presentation.
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which provides insights into the genetic variants in disease and links them with the biological pathways that drive disease in specific patient groups. The company’s pipeline is led by two wholly owned programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for patients. For more information, please visit mazetx.com, or follow the company on LinkedIn and X.
IR/Corporate Contact:
Amy Bachrodt, Maze Therapeutics
abachrodt@mazetx.com
Media Contact:
Dan Budwick, 1AB
dan@1abmedia.com
FAQ
When is Maze Therapeutics (MAZE) presenting at the Jefferies 2025 Global Healthcare Conference?
Who will be presenting for Maze Therapeutics (MAZE) at the Jefferies Healthcare Conference?
How can investors access Maze Therapeutics' (MAZE) presentation at the Jefferies Conference?
What therapeutic areas does Maze Therapeutics (MAZE) focus on?
